Next Article in Journal
Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy
Previous Article in Journal
Systemic Anti-Cancer Therapy and Metastatic Cancer Are Independent Mortality Risk Factors during Two UK Waves of the COVID-19 Pandemic at University College London Hospital
Previous Article in Special Issue
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 23
10.3390/cancers13236087
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Myeloma: A Lot of Progress, Still a Long Way to Go

by
Gábor Mikala
1,* and
Gergely Varga
2
1
Department of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute for Haematology and Infectious Diseases, 1097 Budapest, Hungary
2
Department of Internal Medicine and Haematology, Semmelweis University, 1085 Budapest, Hungary
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(23), 6087; https://doi.org/10.3390/cancers13236087
Submission received: 22 November 2021 / Revised: 29 November 2021 / Accepted: 30 November 2021 / Published: 2 December 2021
(This article belongs to the Special Issue Multiple Myeloma: Targeted Therapy and Immunotherapy)
Versions Notes

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

It was Bart Barlogie who made a clear point by stating in one of his lectures that any myeloma that is not cured will eventually turn into a resistant disease with aggressive clinical behaviour [...]

Share and Cite

MDPI and ACS Style

Mikala, G.; Varga, G. Myeloma: A Lot of Progress, Still a Long Way to Go. Cancers 2021, 13, 6087. https://doi.org/10.3390/cancers13236087

AMA Style

Mikala G, Varga G. Myeloma: A Lot of Progress, Still a Long Way to Go. Cancers. 2021; 13(23):6087. https://doi.org/10.3390/cancers13236087

Chicago/Turabian Style

Mikala, Gábor, and Gergely Varga. 2021. "Myeloma: A Lot of Progress, Still a Long Way to Go" Cancers 13, no. 23: 6087. https://doi.org/10.3390/cancers13236087

APA Style

Mikala, G., & Varga, G. (2021). Myeloma: A Lot of Progress, Still a Long Way to Go. Cancers, 13(23), 6087. https://doi.org/10.3390/cancers13236087

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop